Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

Name: Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
Published: 2022
License: Public Domain

Washington University School of Medicine · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

hpv-unrelated head and neck squamous cell carcinoma, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

Related documents